{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:43:42Z","timestamp":1781826222848,"version":"3.54.5"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>New, lower-cost tests that target high-risk human papillomavirus (HR-HPV) have been developed for cervical cancer screening in lower-resource settings but large, population-based screening studies are lacking. Women ages 25 to 65 years and living in rural China (n = 7,543) self-collected a cervicovaginal specimen, had 2 cervical specimens collected by a clinician, and underwent visual inspection after acetic acid (VIA). The self- and one clinician-collected specimens underwent HR-HPV DNA testing by careHPV (QIAGEN) and Hybrid Capture 2 (HC2; QIAGEN) and the other clinician-collected specimen was tested for HPV16, 18, and 45 E6 using OncoE6 (Arbor Vita Corporation). Women who screened positive for any test and a random sample of those negative on all tests underwent colposcopic evaluation. The percent test positive was 1.8% for HPV E6 oncoprotein, between 14% and 18% for HR-HPV DNA testing, and 7.3% for VIA. The sensitivity for cervical intraepithelial neoplasia grade 3 or more severe (CIN3+; n = 99) was 53.5% for OncoE6, 97.0% for both careHPV and HC2 testing of the clinician-collected specimen, 83.8% for careHPV testing and 90.9% for HC2 testing of the self-collected specimen, and 50.5% for VIA. OncoE6 had the greatest positive predictive value (PPV), at 40.8% for CIN3+, compared with the other tests, which had a PPV of less than 10%. OncoE6 tested 70.3% positive for HPV16, 18, or 45-positive CIN3+ and tested negative for all HPV16-, 18-, or 45-negative CIN3+ (P &amp;lt; 0.0001). HPV E6 oncoprotein detection is useful for identifying women who have cervical precancer and cancer. Cancer Prev Res; 6(9); 938\u201348. \u00a92013 AACR.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-13-0091","type":"journal-article","created":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T00:46:11Z","timestamp":1374540371000},"page":"938-948","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China"],"prefix":"10.1158","volume":"6","author":[{"given":"Fang-Hui","family":"Zhao","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Jeronimo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Lin","family":"Qiao","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schweizer","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Valdez","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Ni","family":"Kang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Bansil","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proma","family":"Paul","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mahoney","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe","family":"Berard-Bergery","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Bai","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Peck","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Stoler","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E.","family":"Castle","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; 2PATH, Seattle, Washington; 3Arbor Vita Corporation, Fremont, California; 4Department of Pathology, University of Virginia, Charlottesville, Virginia; and 5Global Cancer Initiative, Chestertown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,9,3]]},"reference":[{"key":"2022060816202283400_bib1","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.vaccine.2006.05.113","article-title":"Chapter 7: achievements and limitations of cervical cytology screening","volume":"24","author":"Kitchener","year":"2006","journal-title":"Vaccine"},{"key":"2022060816202283400_bib2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int J Cancer"},{"key":"2022060816202283400_bib3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa071430","article-title":"Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer","volume":"357","author":"Mayrand","year":"2007","journal-title":"N Engl J Med"},{"key":"2022060816202283400_bib4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":"Human papillomavirus and Papanicolaou tests to screen for cervical cancer","volume":"357","author":"Naucler","year":"2007","journal-title":"N Engl J Med"},{"key":"2022060816202283400_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(11)70296-0","article-title":"Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial","volume":"13","author":"Rijkaart","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022060816202283400_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022060816202283400_bib7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","article-title":"Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study","volume":"12","author":"Castle","year":"2011","journal-title":"Lancet Oncol"},{"key":"2022060816202283400_bib8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa0808516","article-title":"HPV screening for cervical cancer in rural India","volume":"360","author":"Sankaranarayanan","year":"2009","journal-title":"N Engl J Med"},{"key":"2022060816202283400_bib9","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"key":"2022060816202283400_bib10","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2011.38.8389","article-title":"Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up","volume":"30","author":"Castle","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022060816202283400_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1470-2045(08)70210-9","article-title":"A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China","volume":"9","author":"Qiao","year":"2008","journal-title":"Lancet Oncol"},{"key":"2022060816202283400_bib12","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/ijc.27563","article-title":"Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria","volume":"131","author":"Gage","year":"2012","journal-title":"Int J Cancer"},{"key":"2022060816202283400_bib13","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1128\/JVI.07069-11","article-title":"Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6\/E7 deregulation and the loss of contact inhibition in neoplastic progression","volume":"86","author":"Isaacson Wechsler","year":"2012","journal-title":"J Virol"},{"key":"2022060816202283400_bib14","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1128\/JCM.01315-10","article-title":"Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer","volume":"48","author":"Schweizer","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2022060816202283400_bib15","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022060816202283400_bib16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ajog.2004.02.065","article-title":"Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse","volume":"191","author":"Pretorius","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"2022060816202283400_bib17","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/PAS.0b013e3181e8b2c4","article-title":"Using biomarkers as objective standards in the diagnosis of cervical biopsies","volume":"34","author":"Galgano","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"2022060816202283400_bib18","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1002\/ijc.27571","article-title":"Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies","volume":"131","author":"Zhao","year":"2012","journal-title":"Int J Cancer"},{"key":"2022060816202283400_bib19","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1128\/JCM.37.8.2508-2517.1999","article-title":"Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus","volume":"37","author":"Kleter","year":"1999","journal-title":"J Clin Microbiol"},{"key":"2022060816202283400_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/sim.4780040112","article-title":"A Wilcoxon-type test for trend","volume":"4","author":"Cuzick","year":"1985","journal-title":"Stat Med"},{"key":"2022060816202283400_bib21","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/bjc.2012.441","article-title":"Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya","volume":"107","author":"De Vuyst","year":"2012","journal-title":"Br J Cancer"},{"key":"2022060816202283400_bib22","doi-asserted-by":"crossref","first-page":"e38731","DOI":"10.1371\/journal.pone.0038731","article-title":"HPV genotype distribution in cervical intraepithelial neoplasia among HIV-infected women in Pune, India","volume":"7","author":"Mane","year":"2012","journal-title":"PLoS ONE"},{"key":"2022060816202283400_bib23","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/sj.bjc.6603737","article-title":"Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia","volume":"96","author":"Mane","year":"2007","journal-title":"Br J Cancer"},{"key":"2022060816202283400_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/OLQ.0b013e31823b50ad","article-title":"Human papillomavirus prevalence and type distribution in 3603 HIV-positive and HIV-negative women in the general population of Tanzania: the PROTECT study","volume":"39","author":"Dartell","year":"2012","journal-title":"Sex Transm Dis"},{"key":"2022060816202283400_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djj010","article-title":"Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2","volume":"98","author":"Hawes","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2022060816202283400_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/jnci\/93.11.843","article-title":"Prevalence and risk factors for anal squamous intraepithelial lesions in women","volume":"93","author":"Holly","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2022060816202283400_bib27","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/QAD.0b013e328359f255","article-title":"HPV genotyping, HPV mRNA expression, and p16\/Ki-67 cytology to detect anal cancer precursors in HIV-infected men who have sex with men","volume":"26","author":"Wentzensen","year":"2012","journal-title":"AIDS"},{"key":"2022060816202283400_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022060816202283400_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/318071","article-title":"Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women","volume":"183","author":"Palefsky","year":"2001","journal-title":"J Infect Dis"},{"key":"2022060816202283400_bib30","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1086\/425906","article-title":"Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study","volume":"190","author":"Chin-Hong","year":"2004","journal-title":"J Infect Dis"},{"key":"2022060816202283400_bib31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ijc.25971","article-title":"Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India","volume":"130","author":"Sahasrabuddhe","year":"2012","journal-title":"Int J Cancer"},{"key":"2022060816202283400_bib32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/QAI.0b013e3182426227","article-title":"Cervical cancer prevention in HIV-infected women using the \u201csee and treat\u201d approach in Botswana","volume":"59","author":"Ramogola-Masire","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022060816202283400_bib33","doi-asserted-by":"crossref","first-page":"N1","DOI":"10.1097\/QAD.0b013e3283236e11","article-title":"Implementation of \"see-and-treat\" cervical cancer prevention services linked to HIV care in Zambia","volume":"23","author":"Mwanahamuntu","year":"2009","journal-title":"AIDS"},{"key":"2022060816202283400_bib34","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1309\/PT3PNC1QL2F4D2VL","article-title":"The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report","volume":"127","author":"Castle","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"2022060816202283400_bib35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/AOG.0b013e31818f5008","article-title":"Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2","volume":"113","author":"Castle","year":"2009","journal-title":"Obstet Gynecol"},{"key":"2022060816202283400_bib36","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-04-2599","article-title":"Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype","volume":"11","author":"Trimble","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2022060816202283400_bib37","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/1055-9965.EPI-08-0004","article-title":"Descriptive evidence that risk profiles for cervical intraepithelial neoplasia 1, 2, and 3 are unique","volume":"17","author":"Belinson","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060816202283400_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"2022060816202283400_bib39","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1470-2045(08)70110-4","article-title":"Heterogeneity in CIN3 diagnosis","volume":"9","author":"Schiffman","year":"2008","journal-title":"Lancet Oncol"},{"key":"2022060816202283400_bib40","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"2022060816202283400_bib41","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(10)70256-4","article-title":"Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China","volume":"11","author":"Zhao","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022060816202283400_bib42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jnci\/djr532","article-title":"Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method","volume":"104","author":"Zhao","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2022060816202283400_bib43","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"key":"2022060816202283400_bib44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/AOG.0b013e318168460b","article-title":"An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS)","volume":"111","author":"Castle","year":"2008","journal-title":"Obstet Gynecol"},{"key":"2022060816202283400_bib45","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/S0140-6736(11)61522-5","article-title":"Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial","volume":"378","author":"Lazcano-Ponce","year":"2011","journal-title":"Lancet"},{"key":"2022060816202283400_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3322\/caac.21139","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"62","author":"Saslow","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"2022060816202283400_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/lgt.0b013e31815ea58b","article-title":"Risk assessment to guide the prevention of cervical cancer","volume":"12","author":"Castle","year":"2008","journal-title":"J Low Genit Tract Dis"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/6\/9\/938\/2252519\/938.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/6\/9\/938\/2252519\/938.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T14:21:45Z","timestamp":1654698105000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/6\/9\/938\/50191\/An-Evaluation-of-Novel-Lower-Cost-Molecular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,3]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-13-0091","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1940-6207.22525620","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22525620.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1940-6207.c.6544830.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6544830","asserted-by":"object"}]},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,1]]}}}